je.st
news
New Findings Show Anti-Tumor Activity of KEYTRUDA (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma
2015-09-26 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Achieved Overall Response Rate of 22.2 Percent in Previously-Treated Patients Results from KEYNOTE-028 Presented at 2015 European Cancer Congress KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy in patients with advanced unresectable nasopharyngeal carcinoma (NPC) a type of head and neck cancer whose tumors express PD-L1 (1% of cells in tumor nests or PD-L1+ bands in stroma). Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558An Phan, (908) 255-6325orInvestor:Justin Holko, (908) 740-1879Teri Loxam, (908) 740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: show
advanced
activity
patients
Category:Biotechnology and Pharmaceuticals